Avalon Health Economics is happy to announce the addition of Philipp Schuetz, MD, MPH as our Clinical Advisor. He is a board-certified internist and endocrinologist. He has broad clinical and research interests focusing on the application of new developments in endocrinology, infectious diseases, critical illness and general medicine. He has done extensive research on hormones,…
read moreCEO John Schneider presented at the Barclays HealthCare Symposium on 11/20 on the topic of Increasing Need to Demonstrate Economic Value in Medtech.
read moreThe annual AdvaMed Med Tech Conference is the leading MedTech Conference in North America, bringing more than 1,000 companies together to exchange knowledge and ideas on business development, capital formation, economic evaluation, pricing and reimbursement, educational opportunities and networking. Please let us know if you like to meet and discuss your health economics needs. To…
read moreAvalon Health Economics will be presenting in several venues at the 18th Annual European Congress of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) in Milan, 7-11 November 2015 at the Milano Congressi (MiCo ). The Avalon presentations include: (1) teaching the first ISPOR short course on the Economics of Diagnostics; (2) moderating an…
read moreAvalon at ISPOR: John Schneider, Cara Scheibling, and Ivana Stojanovic will be attending the annual meeting of the International Society of Pharmacoeconomics and Outcomes Research in Philadelphia this week, May 16 through May 20. The title of this year’s meeting is “Integrating Big Data, Patient Data, and Cost-Effectiveness into Clinical Practice: Promise and Prospects.” If…
read moreAvalon CEO John Schneider presents on “The Economics of Molecular Diagnostics” at the University of California Berkeley’s School of Public Health. The lecture covered the basics of molecular diagnostics followed by a more detailed assessment of the costs and benefits of molecular diagnostics. Discussions centered around the value of diagnostics, and how payers and patients…
read moreThe demand for medical care services in the U.S. has long been the envy of other industries. Americans are generally not accustomed to going without, typically despise most non-market forms of rationing, and don’t like government telling them what they can and can’t have. Beneath this culture of consumption lie several layers of public and…
read moreAvalon team publishes study of the U.S. cost impact of procalcitonin testing in acute respiratory infections. In the inpatient setting, the costs of procalcitonin guided compared to usual care for the one million member cohort was $ 2,083,545, compared to $ 2,780,322, resulting in net savings of nearly $ 700,000 to the IDN for 2014.…
read moreJohn Rizzo, PhD, joins Avalon Health Economics as a Consultant. In addition to his role as Consultant with Avalon Health Economics, Dr. Rizzo is Professor of Economics and Preventive Medicine at Stony Brook University (NY) and Chief Economist at the Long Island Association. His research interests include applied economic studies of health care markets and…
read moreCEO John Schneider presented at Nordic Life Science Days in Stockholm, Sweden on the Economic Evaluation of pharmaceutical drugs, medical devices, and diagnostics. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities. Click here to…
read more